CITINGS
Published by the International Myeloma Foundation
Special Edition: ASH 2006
Thalidomide and Revlimid® Issue
The International Myeloma Foundation (IMF) presents this special edition of
CITINGS, our premiere publication featuring the most up-to-date information on myeloma
treatment, focused on thalidomide and Revlimid. This special edition corresponds with the
48th American Society of Hematology (ASH) annual meeting. In this CITINGS, we have
highlighted selected thalidomide and Revlimid data presentations from the ASH meeting.
We also provide references to the latest published journal articles on both thalidomide and
Revlimid from the fourth quarter of this year.
It is our hope that CITINGS will be a valuable tool in keeping you up to date on the latest
developments in myeloma treatment. Please feel free to contact us at (800) 452-CURE or
www.myeloma.org.
— Susie Novis, President, IMF
American Society of Hematology Presentations 2006
Sunday, December 10, 2006
Dexamethasone+Thalidomide (Dex/Thal) Compared to VAD as a Pre-Transplant Treatment in Newly
Diagnosed Multiple Myeloma (MM): A Randomized Trial. Margaret Macro, Marine Divine, Yurdagul Uzunhan, Arnaud Jaccard, Didier Bouscary, Veronique Leblond,
Maud Janvier, Philippe Genet, Sylvie Castaigne, Bruno Royer, Christian Allard, Sylvie Chevret,
Jean-Paul Fermand
Time: 5:00 PM
Location: Room 414 AB
Abstract No: 57
Session Type: Oral Session
Simultaneous Session: Clinical Results: Autologous Transplantation – Multiple Myeloma (4:30PM-6:00PM)
Cardiac Biomarkers Predict for Ability To Tolerate and Complete Therapy with Lenalidomide Dexamathosone in AL Amyloidosis.
Angela Dispenzieri, Martha Lacy, Steven Zeldenrust, Suzanne R. Hayman, Shaji Kumar, Susan M. Geyer,
John A. Lust, Jacob B. Allred, Thomas E. Witzig, S. Vincent Rajkumar, Philip R. Greipp, Stephen J. Russell,
Brian Kabat, Morie Abraham Gertz
Time: 5:15 PM
Location: Chapin Theater, Level III
Abstract No: 130
Session Type: Oral Session
Simultaneous Session: Plasma Cell Dyscrasias, excluding Myeloma and Predictors of Treatment
Outcome (4:30 PM – 6:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)
Funded by an educational grant from Celgene Corporation.
First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) Trial of Thalidomide and
Alternate Day Prednisolone Following Autologous Stem Cell Transplantation (ASCT) for Patients with
Multiple Myeloma (ALLG MM6).
Andrew Spencer, Miles Prince, Andrew W. Roberts, Kenneth F. Bradstock, Ian W. Prosser
Time: 5:15 PM
Location: Room 414 AB
Abstract No: 58
Session Type: Oral Session
Simultaneous Session: Clinical Results: Autologous Transplantation – Multiple Myeloma
(4:30 PM – 6:00 PM)
Timing of Second Autologous Transplantations in Multiple Myeloma: Results of a Multicenter
Sequential Randomized Clinical Trial.
Abderrahman Abdelkefi, Saloua Ladeb, Tarek Ben Othman, Lamia Torjman, Amel Lakhal, Neila Ben
Romdhane, Halima El Omri, Moez Elloumi, Hatem Bellaj, Ramzi Jeddi, Lamia Aissaoui, Fahmi Msadek,
Ali Saad, Mohamed Hsairi, Kamel Boukef, Ahlem Amouri, Hechmi Louzir, Koussay Dellagi,
Abdeladhim Ben Abdeladhim (Intr. by Jean-Francois Rossi)
Time: 5:30 PM
Location: Room 414 AB
Abstract No: 59
Session Type: Oral Session
Simultaneous Session: Clinical Results: Autologous Transplantation – Multiple Myeloma
(4:30 PM–6:00 PM)
Monday, December 11, 2006
Gene Expression Profiling (GEP) of Myeloma (MM) Cells To Predict Attainment (near) Complete
Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed MM.
Carolina Terragna, M. Renzulli, D. Remondini, E. Tagliafico, E. Roncaglia, P. Tosi, E. Zamagni, P. Tacchetti,
G. Perrone, M. Ceccolini, Giovanni Martinelli, M. Baccarani, M. Cavo
Time: 8:30 AM
Location: Chapin Theater, Level III
Abstract No: 245
Session Type: Oral Session
Simultaneous Session: Multiple Myeloma: Pathophysiology and In Vivo Modeling (7:30 AM–9:00 AM)
The Genetic Contribution to the Aetiology of Thalidomide Associated VTE.
Gareth J. Morgan, David C. Johnson, John Crowley, John Shaughnessy, Jr., Pieter Sonneveld, Brian Durie,
Christine Ramos, Brian G. Van Ness, Bart Barlogie, Antje Hoering, Jeff Haessler, Dalsu Baris, Michael Katz,
Vincent S. Rajkumar, H. Goldschmidt
Time: 8:45 AM
Location: Chapin Theater, Level III
Abstract No: 246
Session Type: Oral Session
Simultaneous Session: Multiple Myeloma: Pathophysiology and In Vivo Modeling (7:30 AM–9:00 AM)
www.myeloma.org
(800) 452 - CURE (2873)
Bortezomib and Thalidomide Treatment of Newly Diagnosed Patients with Multiple Myeloma
Efficacy and Neurotoxicity.
Ivan Borrello, Anna Ferguson, Carol Ann Huff, Shirley George, Barbara Biedryzcki, David Cornblath,
Vinay Chaudhry
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #757-III
Abstract No: 3528
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM–7:00 PM)
The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide
(VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of
Dickkopf-1, RANKL, MIP-1 and Angiogenic Cytokines. Evangelos Terpos, Athanasios Anagnostopoulos, Deborah Heath, Efstathios Kastritis, Dimitrios Christoulas,
Nikolaos Anagnostopoulos, Maria Roussou, Konstantinos Tsionos, Peter Croucher, Meletios A. Dimopoulos
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #770-III
Abstract No: 3541
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM–7:00 PM)
Cyclin D1 Overexpression Increases Chemosensitivity Via the Induction of Bim in Myeloma Cells.
Yoshiaki Kuroda, Akira Sakai, Naohiro Tsuyama, Shoso Munemasa, Nanae Nakaju, Mami Mizuno,
Yoshiko Okikawa, Yuta Katayama, Akiro Kimura
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #647-III
Abstract No: 3418
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy II – Gene Regulation
(10:30 AM–7:00 PM)
Erythropoietin Therapy and Venous Thromboembolic Events in Patients with Multiple Myeloma
Receiving Chemotherapy with or without Thalidomide.
Maurizio Zangari, Federica Cavallo, Keshava Prasad, Louis Fink, Sharon Coon, Bart Barlogie, Guido Tricot
Time: 10:30 AM–7:00PM
Location: Hall E1, Board #801-III
Abstract No: 3572
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
Expanded Access Program (EAP) for Lenalidomide (Revlimid) Plus Dexamethasone in over 1400
Subjects with Relapsed or Refractory Multiple Myeloma.
Christine Chen, Donna E. Reece, David Siegel, Ruben Niesvizky, Ralph Vincent Boccia,
Edward A. Stadtmauer, Rafat Abonour, David Irwin, Jonathan Polikoff, Shaji Kumar, Richard A. Gams,
Laurie Kenvin, Dale McElveen, Angela Hu, Dennis Pietronigro, Robert D. Knight, Jerome B. Zeldis
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #785-III
Abstract No: 3556
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)
Final Results of a Phase II Study of Bortezomib (Velcade) in Combination with Liposomal Doxorubicin
(Doxil) and Thalidomide (VDT) Demonstrate a Sustained High Response Rates in Patients (pts) with
Relapsed (rel) or Refactory (ref) Multiple Myeloma.
Asher Alban Chanan-khan, Swaminathan Padmanabhan, Kena C. Miller, Laurie Musiel, Jihnhee Yu,
Zale P. Bernstein, Rami Manochakian, Myron S. Czuczman
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #768-III
Abstract No: 3539
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM–7:00 PM)
Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on MolecularlyDetectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation:
Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction
by Real Time PCR.
Marco Ladetto, Monica Astolfi, Loredana Santo, Ilaria Avonto, Federica Cavallo, Gloria Pagliano,
Patrizia Pregno, Mariella Grasso, Anna Marina Liberati, Tommaso Caravita, Francesco Pisani,
Tommasina Guglielmelli, Elisa Genuardi, Rossana Crivelli, Carmen Cristiano, Daniela Drandi,
Mario Boccadoro, Antonio Palumbo
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #329-III
Abstract No: 3100
Session Type: Poster Session
Poster Session: Clinical Results: Autologous Transplantation – Plasma Cell Dyscrasias (10:30AM–7:00PM)
Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma:
Clinical Implications.
Iris Breitkreutz, Sonia Vallet, Marc S. Raab, Yu-Tzu Tai, Noopur Raje, Teru Hideshima,
Dharminder Chauhan, Nikhil C. Munshi, Paul Richardson, Kenneth C. Anderson
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #714-III
Abstract No: 3485
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy V – Therapeutic
Implications (10:30 AM–7:00 PM)
Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First
Relapse in Relapsed Multiple Myeloma.
Edward Stadtmauer, Donna Weber, M. Dimopolous, Andrew Belch, Michel Attal, Miles Prince,
Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, Robert Knight
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #781-III
Abstract No: 3552
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)
Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to
Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM).
Asher Alban Chanan-Khan, Donna Weber, Meletius Dimopoulos, Christine Chen, Reuben Niesvizky,
Michael Wang, Andrew Belch, Michel Attal, Andrew Spencer, Miles Prince, Marta Olesnyckyj, Jerome Zeldis,
Zhinuan Yu, Robert Knight
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #780-III
Abstract No: 3551
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to
Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref)
Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.
Asher Alban Chanan-Khan, Zhinuan Yu, Donna Weber, Christine Chen, Ruben Niesvizky,
Andrew Spencer, Michel Attal, Andrew Belch, Miles Prince, Marta Olesnyckyj, Robert Knight,
Jerome Zeldis, Meletius Dimopoulos
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #783-III
Abstract No: 3554
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in
Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma.
Michael Wang, Robert Knight, Melitios Dimopoulos, David Siegel, S. Vincent Rajkumar, Thierry Facon,
Raymond Alexanian, Zhinuan Yu, Jerome Zeldis, Marta Olesnyckyj, Donna Weber
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #782-III
Abstract No: 3553
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
Lenalidomide Induced Myelosupression Is Potentially Associated with Renal Dysfunction in Treatment
Nave Myeloma (MM) Patients Receiving BiRD (Biaxin/Revlimid/Dexamethasone) Combination
Therapy (Rx).
Ruben Niesvizky, D.S. Jayabalan, F. Zafar, P. Christos, R. Lent, R. Pearse, J. Tepler, S. Ely, T. Shore, J. Harpel,
M. Schuster, K. Pekle, J.B. Jalbrzikowski, H.J. Cho, J. Leonard, M. Mazumdar, S. Chen-Kiang, M. Coleman
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #778-III
Abstract No: 3549
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
Lenalidomide Overcomes Poor Prognosis Conferred by Deletion of Chromosome 13 and t(4;14) in
Multiple Myeloma: MM016 Trial.
Nizar J. Bahlis, Adnan Mansoor, Johannes C. Lategan, Karen Valentine, Tedd Thaell, Walter Blahey,
Mary Lynn Savoie, Kim Blaikie, Leanne Kmet, Birgitte Roland, Douglas A. Stewart
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #786-III
Abstract No: 3557
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)
Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to
High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of
2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal
Function.
Donna Weber, Michael Wang, Christine Chen, Andrew Belch, Edward A. Stadtmauer, Ruben Niesvisky,
Zhinuan Yu, Marta Olesnyckyj, Jerome Zeldis, Robert D. Knight, Meletios Dimopoulos
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #776-III
Abstract No: 3547
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
Lenalidomide (Revlimid) +/- Corticosteroids in Elderly Patients with Relapsed/Refractory
Multiple Myeloma.
Donna E. Reece, Esther Masih-Khan, Christine Chen, Lisa Wang, Saima Dean, Suzanne Trudel,
Joseph R. Mikhael, Vishal Kukreti, Robert Knight, Jerome Zeldis
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #779-III
Abstract No: 3550
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
Lenalidomide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an
Effective Regimen for Heavily Pre-Treated Myeloma Patients.
Gareth J. Morgan, Stephen Schey, Ping Wu, M. Srikanth, Karen J. Phekoo, Matthew W. Jenner, Sharon Dines,
Radovan Saso, Faith E. Davies
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #784-III
Abstract No: 3555
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or
Indolent) Myeloma.
Suzanne Hayman, Morie Gertz, Martha Lacy, Angela Dispenzieri, Rafael Fonseca, Susan Geyer, Shaji Kumar,
Steven Zeldenrust, Stephen Russell, John Lust, Robert Kyle, Philip Greipp, Thomas Witzig,
S. Vincent Rajkumar
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #797-III
Abstract No: 3568
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)
Low Efficacy of Thalidomide in Improving Response after Induction in Myeloma Patients Candidate
to High-Dose Therapy.
Alessandro Corso, Silvia Mangiacavalli, Luciana Barbarano, Patrizia Zappasodi, Luciano Banfi,
Luigi Montalbetti, Antonio Mazzone, Sergio Fava, Guido Frigerio, Luciano Isa, Sergio Montanara,
Daniele Perego, Maria Savarè, Lilj Uziel, Alessandro Vismara, Leonardo Campiotti, Mario Fiumanò,
Mario Lazzarino, Enrica Morra
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #796-III
Abstract No: 3567
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
Melphalan (M), Prednisone (P) and Lenalidomide (R) Combination (MPR) for Newly Diagnosed
Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation.
Vivek, Roy; Bergsagel, P. Leif; Allred, Jacob; Greipp, R. Philip
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #787-III
Abstract No: 3558
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Avanced
Multiple Myeloma Patients.
Antonio Palumbo, Cecilia Rus, Davide Rossi, Patrizia Pregno, Maria Teresa Ambrosini, Ilaria Avonto,
Francesca Gay, Federica Cavallo, Massimo Iacobelli, Gianluca Gaidano, Constantine Mitsiades,
Paul G. Richardson, Kenneth C. Anderson, Mario Boccadoro
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #789-III
Abstract No: 3560
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral
Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.
Ingo G.H. Schmidt-Wolf, Thomas Moehler, Hartmut Goldschmidt, Thomas Geer, Rolf Kleinschmidt,
Tobias Gaska, Uwe Janssens, Joerg Schubert, Patrick Brueck, Michael R. Clemens, Wolfgang Bair,
Gernot Seipelt, Michael Schleuning, Corinna Hahn-Ast, Susanne Herz, Marie von Lilienfeld-Toal,
Ralph Naumann, Marcus Gorschlueter, Axel Glasmacher
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #788-III
Abstract No: 3559
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)
Polychemotherapy in Combination with Thalidomide Followed by Autologous or Allogeneic
Transplantation for Rescue after Autograft or Induction Therapy Failure in Patients with Multiple
Myeloma.
Ute Hegenbart, Stefan O. Schonland, Thomas Moehler, Axel Benner, Sabine Gerull, Martin Goerner,
Hans-Joerg Schaefer, Gerlinde Egerer, Peter Dreger, Anthony D. Ho, Hartmut Goldschmidt
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #247-III
Abstract No: 3018
Session Type: Poster Session
Poster Session: Clinical Results: Allogeneic Matched Related Donor Transplantation I (10:30 AM–7:00 PM)
Pulsed Cyclophoshamide, Thalidomide and Dexamethasone (CTD) Regimen for Previously Treated
Patients with Multiple Myeloma: Long Term Follow up and Disease Control after Subsequent
Treatments.
Maria Roussou, Athanasios Anagnostopoulos, Efstathios Kastrtis, Charis Matsouka, Despina Barmparoussi,
Vasiliki Koutsoukou, Meletios A. Dimopoulos
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #794-III
Abstract No: 3565
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
RADAR Update on Thalidomide (Thal)- and Lenalidomide (Len)-Associated Venous
Thromboembolism (VTE): Safety Concerns Persist for Multiple Myeloma (MM) Despite FDA
Approvals in This Setting.
Charles L. Bennett, Zehra Hussain, Mark Courtney, Paul Yarnold, Dennis Raisch, June M. McKoy
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #539-III
Abstract No: 3310
Session Type: Poster Session
Poster Session: Health Services and Outcomes Research: Malignant Hematology (10:30 AM–7:00 PM)
A Randomized Comparison of Dexamethasone + Thalidomide (Dex/Thal) vs Dex + Placebo (Dex/P)
in Patients (pts) with Relapsing Multiple Myeloma (MM).
Jean-Paul Fermand, Arnaud Jaccard, Margaret Macro, Yurdagul Uzunhan, Christian Allard, Sylvie Castaigne,
Marine Divine, Xavier Mariette, Veronique Leblond, Sylvie Chevret
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #792-III
Abstract No: 3563
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
Retrospective Analysis of Fractionated High-Dose Melphalan (F-MEL) and Bortezomib-ThalidomideDexamethasone (VTD) with Autotransplant (AT) Support for Advanced and Refractory Multiple
Myeloma (AR-MM).
Mauricio Pineda-Roman, Michelle H. Fox, Klaus A. Hollmig, Elias J. Anaissie, Frits van Rhee, Guido Tricot,
Maurizio Zangari, Abid Mohiuddin, Bart Barlogie
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #331-III
Abstract No: 3102
Session Type: Poster Session
Poster Session: Clinical Results: Autologous Transplantation – Plasma Cell Dyscrasias (10:30 AM–7:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)
S0204: Melphalan (MEL)-Based Tandem Autotransplants (TAT) for Multiple Myeloma (MM)
with Thalidomide/Dexamethasone (TD) Induction and Thalidomide/Prednisone (TP) Maintenance:
A Phase II Trial of the Southwest Oncology Group.
Mohamad A. Hussein, Andrzej J. Jakubowiak, Vanessa Bolejack, Jeff Zonder, John Crowley, Bart Barlogie
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #317-III
Abstract No: 3088
Session Type: Poster Session
Poster Session: Clinical Results: Autologous Transplantation – Plasma Cell Dyscrasias (10:30 AM–7:00 PM)
Survival Outcomes of Patients Receiving Thalidomide-Dexamethasone for Previously Untreated
Multiple Myeloma.
Sheeba K. Thomas, Sergio A. Giralt, Michael Wang, Kay B. Delasalle, Maria Gavino, Kim Rankin,
Raymond Alexanian, Donna M. Weber
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #798-III
Abstract No: 3569
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
A Systematic Review and Meta-Analysis of Thalidomide in Patients with Previously Untreated
Multiple Myeloma.
Lisa Hicks, Adam Haynes, Donna E. Reece, Irwin Walker, Jordan A. Herst, Kevin Imrie
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #799-III
Abstract No: 3570
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM-7:00 PM)
Tandem Cycle High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Maintenance
Interferon Alpha-2 (IF) with or without Thalidomide (Thal) Is Associated with High Complete and
Very Good Partial Response Rates, Improved Progression-Free, and Overall Survival.
George Somlo, Dajun Qian, Firoozeh Sahebi, Neil Martin Kogut, Roberto Rodriguez, Pablo Miguel Parker,
Leslie Popplewell, Amrita Krishnan, Joycelynne Palmer, Anthony Selwyn Stein, Ricardo Spielberger,
Jeffrey Schriber, Joseph Alvarnas, Warren Chow, Auayporn Nademanee, Jasmine M. Zain,
Margaret R. O’Donnell, Stephen J. Forman
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #318-III
Abstract No: 3089
Session Type: Poster Session
Poster Session: Clinical Results: Autologous Transplantation – Plasma Cell Dyscrasias (10:30AM–7:00PM)
www.myeloma.org
(800) 452 - CURE (2873)
Thalidomide-Dexamethasone (Thal-dex) vs Interferon--Dexamethasone (IFN-dex) as Maintenance
Treatment after ThaDD Induction for Multiple Myeloma (MM): First Analysis of a Prospective
Randomized Study.
Massimo Offidani, Laura Corvatta, Claudia Polloni, Maria-Novella Piersantelli, Piero Galieni,
Giuseppe Visani, Francesco Alesiani, Massimo Catarini, Marino Brunori, Maurizio Burattini,
Riccardo Centurioni, Mario Ferranti, Luciano Giuliodori, Marco Candela, Monica Marconi, Pietro Leoni
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #795-III
Abstract No: 3566
Session Type: Poster Sessio
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
Time to First Progression, but Not 2-Microglobulin, Predicts Outcome in Myeloma Patients Who
Received Thalidomide as Salvage Therapy.
Antonio Palumbo, Sara Bringhen, Patrizia Falco, Cecilia Rus, Federica Cavallo, Maria Teresa Ambrosini,
Ilaria Avonto, Francesca Gay, Gabriele Gallone, Tommaso Caravita, Benedetto Bruno, Mario Boccadoro
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #791-III
Abstract No: 3562
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
Treatment Associated Venous Thromboembolism (VTE) and Survival in Multiple Myeloma Patients.
Maurizio Zangari, Federica Cavallo, Louis M. Fink, Bart Barlogie, Vanessa Bolejack, Michael J. Burns,
Elias Anaissie, Klaus A. Hollmig, Abid Mohiuddin, Mauricio Pineda-Roman, Guido J. Tricot
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #802-III
Abstract No: 3573
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
Treatment with Bendamustine, Thalidomide and Prednisolone (BPT) in Patients with Refractory
or Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation or Conventional
Chemotherapy: Results of a Phase I Clinical Trial.
Wolfram Poenisch, Marta Rozanski, Hartmut Goldschmidt, Franz-Albert Hoffmann, Thomas Boldt, Andreas
Schwarzer, Ute Ruffert, Robert Rohrberg, Elke Schwalbe, Jens Uhlig, Thomas Zehrfeld, Veronika Schirmer,
Antje Haas, Ute Kreibich, Dietger Niederwieser
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #793-III
Abstract No: 3564
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)
Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double
TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic
Implications of Chromosome 13 Deletion and Translocation t(4;14).
Michele Cavo, Nicoletta Testoni, Carolina Terragna, Elena Zamagni, Paola Tacchetti, Chiara Nicci, Matteo
Renzulli, Elena Montanari, Giulia Perrone, Delia Cangini, Tiziana Grafone, Michela Ceccolini, AnnaMaria
Brioli, Giovanni Martinelli, Patrizia Tosi, Michele Baccarani
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #310-III
Abstract No: 3081
Session Type: Poster Session
Poster Session: Clinical Results: Autologous Transplantation – Plasma Cell Dyscrasias (10:30 AM–7:00 PM)
An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed
Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors
(SPF) and Gene Expression Profiling (GEP)-Derived Subgroups.
John D. Shaughnessy, Jr., Jeffrey Haessler, Jerry Zeldis, Yongsheng Huang, Fenghuang Zhan, Jeffrey Sawyer,
Elias Anaissie, Frits van Rhee, Guido Tricot, Joshua Epstein, Maurizio Zangari, Mauricio Pineda-Roman,
Klaus Hollmig, John Crowley, Bart Barlogie
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #618-III
Abstract No: 3389 Session Type: Poster Session
Poster Session: Health Services and Outcomes Research: Malignant Hematology (10:30 AM–7:00 PM)
Use of Lenalidomide (Revlimid +/- Corticosteroids in Relapsed/Refractory Multiple Myeloma Patients
with Elevated Baseline Serum Creatinine Levels.
Donna E. Reece, Esther Masih-Khan, Christine Chen, Lisa Wang, Saima Dean, Vishal Kukreti,
Joseph R. Mikhael, Suzanne Trudel, Robert Knight, Jerome Zeldis
Time: 10:30 AM–7:00 PM
Location: Hall E1, Board #777-III
Abstract No: 3548
Session Type: Poster Session
Poster Session: Myeloma: Immumomodulatory-Based Therapies (10:30 AM–7:00 PM)
Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM):
Final Results of a Multicenter Phase 1 Trial.
Paul G. Richardson, S. Jagannath, D.E. Avigan, M. Alsina, R.L. Schlossman, A. Mazumder, N.C. Munshi, I.
Ghobrial, D. Doss, M.L. McKenney, M.G. Farrell, D.L. Warren, L.E. Lunde, B. Gourley, S. Vaccaro,
C. Delaney, S. Pountney, C.S. Mitsiades, T. Hideshima, C. Byrne, R. Knight, A. Birner, T. Myers, E. Weller,
K.C. Anderson
Time: 11:30 AM
Location: Chapin Theater, Level III
Abstract No: 405
Session Type: Oral Session
Simultaneous Session: Treatment of Relapsed/Refractory Myeloma (11:00 AM–12:30 PM)
www.myeloma.org
(800) 452 - CURE (2873)
Combination of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) for Relapsed Multiple
Myeloma: Results of a Phase I/II Clinical Trial.
Antonio Palumbo, Maria Teresa Ambrosini, Giulia Benevolo, Patrizia Pregno, Norbert Pescosta,
Vincenzo Callea, Clotilde Cangialosi, Tommaso Caravita, Fortunato Morabito, Pellegrino Musto,
Sara Bringhen, Francesca Gay, Cecilia Rus, Mario Boccadoro
Time: 12:00PM
Location: Chapin Theater, Level III
Abstract No: 407
Session Type: Oral Session
Simultaneous Session: Treatment of Relapsed/Refractory Myeloma (11:00 AM–12:30 PM)
Lenalidomide (Revlimid), Adriamycin and Dexamethasone Chemotherapy (RAD) Is Safe and Effective
in Treatment of Relapsed Multiple Myeloma First Results of a German Multicenter Phase I/II Trial.
Stefan Knop, Christian Gerecke, Max S. Topp, Peter Liebisch, Georg Hess, Sandra Kotkiewitz,
Hermann Einsele, Ralf Bargou
Time: 12:15 PM
Location: Chapin Theater, Level III
Abstract No: 408 Session Type: Oral Session
Simultaneous Session: Treatment of Relapsed/Refractory Myeloma (11:00 AM–12:30 PM)
Tuesday, December 12, 2006
VAD-doxil vs.VAD-doxil Plus Thalidomide as Initial Treatment in Patients with Multiple Myeloma:
A Multicenter Randomized Trial of the Greek Myeloma Study Group.
Konstantinos Zervas, Dimitra Mihou, Irini Katodritou, Anastasia Pouli, Chrisanthi H. Mitsouli,
Athanasios Anagnostopoulos, Souzana Delimbasi, Marie-Christine Kyrtsonis, Nikolaos Anagnostopoulos,
Evangelos Terpos, Panagiotis Zikos, Meletios A. Dimopoulos
Time: 8:15 AM
Location: Halls F1-F2
Abstract No: 794
Session Type: Oral Session
Simultaneous Session: Induction Therapy for Newly Diagnosed Myeloma (8:00 AM–10:00 AM)
A Randomized, Double-Blind, Placebo-Controlled Trial of Thalidomide Plus Dexamethasone Versus
Dexamethasone Alone as Primary Therapy for Newly Diagnosed Multiple Myeloma.
S. Vincent Rajkumar, Mohamad Hussein, John Catalano, Wieslaw Jedrzejcak, Svetlana Sirkovich,
Marta Olesnyckyj, Zhinuan Yu, Robert Knight, Jerry Zeldis, Joan Blade
Time: 8:30 AM
Location: Halls F1-F2
Abstract No: 795
Session Type: Oral Session
Simultaneous Session: Induction Therapy for Newly Diagnosed Myeloma (8:00 AM–10:00 AM)
Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy,
Time to Progression, and Survival.
Martha Lacy, Morie Gertz, Angela Dispenzieri, Suzanne Hayman, Susan Geyer, Steven Zeldenrust,
Shaji Kumar, Philip Greipp, Rafael Fonseca, John Lust, Stephen Russell, Robert Kyle, Thomas Witzig,
Leif Bergsagel, S. Vincent Rajkumar
Time: 9:15 AM
Location: Halls F1-F2
Abstract No: 798
Session Type: Oral Session
Simultaneous Session: Induction Therapy for Newly Diagnosed Myeloma (8:00 AM–10:00 AM)
www.myeloma.org
(800) 452 - CURE (2873)
A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide
Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated
by the Eastern Cooperative Oncology Group.
S. Vincent Rajkumar, Susanna Jacobus, Natalie Callander, Rafael Fonseca, David Vesole, Philip Greipp
Time: 9:30 AM
Location: Halls F1-F2
Abstract No: 799
Session Type: Oral Session
Simultaneous Session: Induction Therapy for Newly Diagnosed Myeloma (8:00 AM–10:00 AM)
Oral Revlimid Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma:
Results of a Multicenter Phase I/II Study.
Antonio Palumbo, Patrizia Falco, Antonietta Falcone, Paolo Corradini, Francesco Di Raimondo, Nicola
Giuliani, Giuseppe Rossi, Fortunato Morabito, Letizia Canepa, Alessandro Gozzetti, Maria Teresa Ambrosini,
Jerome Zeldis, Robert Knight, Robin Foà, Mario Boccadoro, Maria Teresa Petrucci
Time: 9:45 AM
Location: Halls F1-F2
Abstract No: 800
Session Type: Oral Session
Simultaneous Session: Induction Therapy for Newly Diagnosed Myeloma (8:00 AM–10:00 AM)
Publication Only
Effects of Thalidomide on Platelets: Possible Causes of Hypercoagulability and Thrombocytopenia.
Holavanahalli Keshava-Prasad, Varsha Kaushal, Paulette Mehta
Abstract No: 3969
Session Type: Publication Only
Maintenance Therapy with Low Dose Thalidomide, Dexamethasone and Clarithromycin (Biaxin)
(BLT-D) Following Autologous Transplant (ASCT) for Multiple Myeloma (MM).
Leona A. Holmberg, Aurora Brandvold, William I. Bensinger
Abstract No: 5442
Session Type: Publication Only
Quantitative Detection Using SYBR Green of Residual Disease in Myeloma Patients Treated with
Revlimid or Velcade.
Kyle J. Thulien, Tony Reiman, Andrew R. Belch, Johnathan Booth, Linda M. Pilarski
Abstract No: 5102
Session Type: Publication Only
Thalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma.
Johnny McHugh, Cathal O’Ceallaigh, Colm Keane, Brian W. Otridge, Peter O’Gorman
Abstract No: 5120
Session Type: Publication Only
Thalidomide (HAL) Maintenance Following High-Dose Melphalan with Autologous Stem Cell
Transplant (ASCT) for Myeloma.
Julie E. Chang, Mark B. Juckett, Brad S. Kahl, Teri L. Mitchell, Ronald E. Gangnon, Natalie S. Callander,
Walter L. Longo
Abstract No: 5455
Session Type: Publication Only
www.myeloma.org
(800) 452 - CURE (2873)
Thalidomide Plus Dexamethasone for Untreated Newly Diagnosed Multiple Myeloma Patients and
Deep Vein Thrombosis.
Victor H. Jiménez, Virginia J. Domínguez, Eduardo E. Reynoso
Abstract No: 5093
Session Type: Publication Only
Thalidomide-Induced Leukopenia in Japanese Patients with Refractory Multiple Myeloma.
Hirokazu Murakami, Hiroshi Handa, Masahiro Abe, Shinsuke Iida, Akihiro Ishii, Takayuki Ishikawa,
Tadao Ishida, Masatsugu Oota, Shuji Ozaki, Masaaki Kosaka, Akira Sakai, Morio Sawamura,
Kazuaki Shimizu, Toshiyuki Takagi, Hiroyuki Hata, Takashi Fukuhara, Hiroshi Fujii, Akira Miyata,
Toshio Wakayama, Kiyoshi Takatsuki
Abstract No: 5089
Session Type: Publication Only
Thromboprophylaxis with Aspirin for Newly Diagnosed Multiple Myeloma Treated with Thalidomide
Plus Dexamethasone: A Preliminary Report.
Victor H. Jimenez, Virginia Dominguez, Eduardo Reynoso, Indira Lopez
Abstract No: 5091
Session Type: Publication Only
Trauma Site Localisation of Extramedullary Plasmacytomata in Thalidomide Treated
Myeloma Patients.
James Cavet, Hamish Hunter, Gordon Cook (Intr. by Graham Hunter Jackson)
Abstract No: 5069
Session Type: Publication Only
Treatment of Newly Diagnosed, Inner-City Multiple Myeloma Patients with Zoledronate,
Dexamethasone, and Low-Dose Thalidomide: A Phase II Trial.
Uwe Klueppelberg, Eric L.P. Smith, Marc J. Braunstein, David Kahn, Olcay A. Batuman
Abstract No: 5124
Session Type: Publication Only
www.myeloma.org
(800) 452 - CURE (2873)
4th Quarter 2006 Thalidomide and Revlimid® Publications
A cure for multiple myeloma? [Article in French]
Harousseau JL.
Presse Med. 2006 Sep;35(9 Pt 2):1288-90.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16969322&query_hl=3&itool=pubmed_DocSum
No abstract available.
New drugs for myeloma [Article in French]
Moreau P.
Presse Med. 2006 Sep;35(9 Pt 2):1303-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16969325&query_hl=1&itool=pubmed_DocSum
The author discusses thalidomide, bortezomib, and lenalidomide treatment alone and in combination,
concluding that their effectiveness in combination will result in their eventual replacement of conventional myeloma chemotherapies.
Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
Raje N, Hideshima T, Anderson KC.
Expert Rev Anticancer Ther. 2006 Sep;6(9):1239-47.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17020458&query_hl=3&itool=pubmed_DocSum
The authors review the preclinical and clinical activity of thalidomide and its more potent immunomodulatory derivatives that are used to treat multiple myeloma, which have shown remarkable responses
in myeloma patients.
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase II trial.
Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, Skinner M, Seldin DC.
Blood. 2006 Sep 7; [Epub ahead of print.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16960148&query_hl=1&itool=pubmed_DocSum
The authors discuss successful treatment regimens used in multiple myeloma and assess their potential
for the treatment of AL amyloidosis. Findings from their trial indicate that lenalidomide can be an
effective AL amyloidosis treatment.
www.myeloma.org
(800) 452 - CURE (2873)
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory
multiple myeloma: safety and efficacy.
Baz R, Walker E, Karam MA, Choueiri TK, Jawde RA, Bruening K, Reed J, Faiman B, Ellis Y, Brand C,
Srkalovic G, Andresen S, Knight R, Zeldis J, Hussein MA.
Ann Oncol. 2006 Sep 15; [Epub ahead of print.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16980599&query_hl=24&itool=pubmed_DocSum
The authors conduct a phase I/II trial of the combination of lenalidomide and chemotherapy to evaluate the safety and efficacy of the combination, and find the treatment well tolerated and resulting in
high response rates in their mostly refractory patient population.
Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on
response duration.
Cibeira MT, Rosinol L, Ramiro L, Esteve J, Torrebadell M, Blade J.
Eur J Haematol. 2006 Sep 15; [Epub ahead of print.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16978238&query_hl=1&itool=pubmed_DocSum
The authors study the quality and duration of multiple myeloma (MM) treatment response to thalidomide administered as a single agent. They find that the effect of thalidomide in refractory/relapsed MM
can be sustained, particularly in patients who achieve a greater degree of response, and they support the
finding that thalidomide can be used for maintenance therapy.
Development of neuropathy in patients with myeloma treated with thalidomide: patterns of
occurrence and the role of electrophysiologic monitoring.
Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM.
J Clin Oncol. 2006 Sep 20;24(27):4507-14. [Epub 2006 Aug 28.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16940275&query_hl=1&itool=pubmed_DocSum
The authors assess the time course of occurrence, possible predictive factors, and the utility of serial
nerve electrophysiological studies for detecting the onset of neuropathy associated with thalidomide
treatment for multiple myeloma. The authors find that the majority of patients will develop peripheral
neuropathy given sufficient length of treatment with thalidomide and to minimize the risk of neurotoxicity, therapy should be limited to less than 6 months. In addition, they find that electrophysiologic
monitoring provides no clear benefit versus careful clinical evaluation for the development of clinically
significant neuropathy.
www.myeloma.org
(800) 452 - CURE (2873)
Safety and efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic
AL amyloidosis.
Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD.
Blood. 2006 Sep 21; [Epub ahead of print.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16990593&query_hl=3&itool=pubmed_DocSum
The authors report the use of a risk adapted oral regimen of cyclophosphamide, thalidomide and dexamethasone (CTD) or attenuated CTD (CTDa) in 75 patients with advanced AL amyloidosis. They
find clonal response rates to CTD to be higher than any previously reported non-transplant regimen in
AL amyloidosis, and that the regimen’s risk adaptation allows its use in poorer risk patients.
The activity of lenalidomide with or without dexamethasone in patients with primary systemic
amyloidosis.
Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE,
Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA.
Blood. 2006 Sep 28; [Epub ahead of print.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17008538&query_hl=18&itool=pubmed_DocSum
The authors study the toxicity and efficacy of lenalidomide in patients with amyloidosis (AL) and find
limited activity of single agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation.
Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
Sviggum HP, Davis MD, Rajkumar SV, Dispenzieri A.
Arch Dermatol. 2006 Oct;142(10):1298-302.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17043184&query_hl=18&itool=pubmed_DocSum
This study addresses dermatologic adverse effects of lenalidomide in patients with amyloidosis (AL) and
multiple myeloma (MM). The authors find that the prevalence of dermatologic adverse effects in patients
receiving lenalidomide was higher in those with AL than those with MM, and that with both sets of
patients, most skin eruptions were mild and did not necessitate withdrawal of lenalidomide therapy.
Hypothyroidism caused by thalidomide.
Chowta MN, Chowta NK.
Indian J Med Sci. 2006 Oct;60(10):424-6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17006030&query_hl=1&itool=pubmed_DocSum
No abstract available.
www.myeloma.org
(800) 452 - CURE (2873)
Recent advances in the treatment of Multiple Myeloma.
Yasui H, Hideshima T, Richardson PG, Anderson KC.
Curr Pharm Biotechnol. 2006 Oct;7(5):381-93.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17076653&query_hl=3&itool=pubmed_DocSum
The authors discuss the mechanisms of action of novel drugs (including thalidomide/Thalomid and lenali­
domide/Revlimid) and their clinical applications, alone or combined with conventional or novel drugs.
Thalidomide in multiple myeloma: past, present and future.
Harousseau JL.
Future Oncol. 2006 Oct;2(5):577-89.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17026450&query_hl=3&itool=pubmed_DocSum
The author discusses thalidomide as one of the most active agents in relapsed myeloma and, demonstrated more recently, its use as part of frontline therapy.
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than
65 years with newly diagnosed multiple myeloma.
Offidani M, Corvatta L, Piersantelli MN, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini
M, Centurioni R, Ferranti M, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M,
Olivieri A, Poloni A, Polloni C, Marconi M, Leoni P.
Blood. 2006 Oct 1;108(7):2159-64. [Epub 2006 Jun 8.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16763209&query_hl=1&itool=pubmed_DocSum
The authors present the results of a phase II study using thalidomide, dexamethasone, and pegylated
liposomal doxorubicin (ThaDD) in the treatment of 50 patients older than 65 years with newly diagnosed multiple myeloma. They find that in the treatment of these patients, ThaDD is a very effective
regimen with manageable toxicity.
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, Schlossman R, Ghobrial I,
Raje N, Munshi N, Anderson KC.
Oncogene. 2006 Oct 2; [Epub ahead of print.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17016430&query_hl=1&itool=pubmed_DocSum
The authors characterize the effects of ABT-737, a potent small-molecule protein inhibitor, and finds
that combining ABT-737 with bortezomib, melphalan, or dexamethasone induces additive anti-multiple
myeloma activity.
www.myeloma.org
(800) 452 - CURE (2873)
Can thalidomide improve outcome in patients with multiple myeloma?
Richardson PG, Mitsiades CS, Munshi NC, Anderson KC.
Nat Clin Pract Oncol. 2006 Nov;3(11):590-1.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17080171&query_hl=3&itool=pubmed_DocSum
No abstract available.
The pharmacokinetics of low-dose thalidomide in Japanese patients with refractory
multiple myeloma.
Kamikawa R, Ikawa K, Morikawa N, Asaoku H, Iwato K, Sasaki A.
Biol Pharm Bull. 2006 Nov;29(11):2331-4.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17077542&query_hl=3&itool=pubmed_DocSum
The thalidomide dosage used for the treatment of refractory multiple myeloma patients in Japan is
lower than that in other countries. In this study, the authors aim to characterize the pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma, and to examine the
relationship between pharmacokinetics and adverse events.
Thrombomodulin levels are not modified during thalidomide treatment.
Zappasodi P, Mangiacavalli S, Terulla V, Airo F, Klersy C, Varettoni M, Corso A.
Eur J Haematol. 2006 Nov;77(5):453-4.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17044838&query_hl=3&itool=pubmed_DocSum
No abstract available.
www.myeloma.org
(800) 452 - CURE (2873)
www.myeloma.org
(800) 452 - CURE (2873)